Circulating matrix metalloproteinase-9 and osteoporosis in patients with chronic obstructive pulmonary disease

• Published in: Chronic respiratory disease 2009-05, Vol.6 (2), p.81-87
• Main Authors: Bolton, CE, Stone, MD, Edwards, PH, Duckers, JM, Evans, WD, Shale, DJ
• Format: Article
• Language: English
• Subjects: Aged; Biomarkers - blood; Bone Density; Case-Control Studies; Cohort Studies; Female; Forced Expiratory Volume; Humans; Inflammation Mediators - blood; Male; Matrix Metalloproteinase 9 - blood; Middle Aged; Osteoporosis - diagnosis; Osteoporosis - enzymology; Osteoporosis - epidemiology; Pulmonary Disease, Chronic Obstructive - blood; Pulmonary Disease, Chronic Obstructive - complications; Pulmonary Disease, Chronic Obstructive - enzymology; ROC Curve; Severity of Illness Index; Tissue Inhibitor of Metalloproteinase-1 - blood; Tissue Inhibitor of Metalloproteinase-2 - blood
• ISSN: 1479-9731; 1479-9723; 1479-9731
• DOI: 10.1177/1479972309103131

Matrix metalloproteinase-9 (MMP-9) has been implicated in airways injury in chronic obstructive pulmonary disease (COPD). Osteoporosis is common in patients with COPD, and MMP-9 is an indicator of activated osteoclasts. We hypothesized that circulating MMP-9 would be related to bone mineral density (BMD) in COPD. We explored the relationship between MMP-9, tissue inhibitors of metalloproteinases (TIMP)-1 and -2, and BMD status in patients with COPD. A total of 70 clinically stable patients with confirmed COPD and 39 control subjects underwent spirometry, dual-energy x-ray absorptiometry to determine BMD, and venous sampling for measurement of cytokines and MMP-9 and TIMP-1 and -2. In patients, circulating MMP-9 was increased: mean (SD) 38.5 (2.2) compared with control subjects 20.1 (2.0) ng/mL, P